Indian pharma major Lupin announced today the U.S. launch of Risperidone extended-release injectable suspension in 25 mg, 37.5 mg and 50 mg single-dose vials, marking a significant strategic move in the long-acting injectable (LAI) market...
AstraZeneca’s Baxdrostat has achieved a major milestone in the treatment of resistant hypertension (rHTN).Phase III trials demonstrate very large and long-term improvements in blood-pressure. The drug blocks the hormone aldosterone by inhibiting...
Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., has announced new findings from the ongoing real-world IMPACT-TD Registry, which underscore the beneficial effects of AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR
Granules India announced that its subsidiary, Granules Life Sciences (GLS), based in Hyderabad, has obtained approval from the U.S. Food and Drug Administration (FDA) for a product that underwent a pre-approval inspection (PAI)
Glenmark Specialty S.A.,a subsidiary of Glenmark Pharmaceuticals Ltd. that is fully owned, announced that its innovative nasal spray for allergic rhinitis, Ryaltris Compound Nasal Spray (GSP 301 NS), has received approval from China
Marksans Pharma experienced an increase of 1.94%, reaching Rs 186.30, following the announcement that it received zero observations during a current Good Manufacturing Practice (cGMP) inspection conducted by the US Food and Drug Administration
The Johnson & Johnson's (J&J) CAPLYTA (lumateperone) product has been given a green light by the U.S. Food and Drug Administration (USFDA) to be used as adjunctive therapy with antidepressants for adult major depressive disorder
The transition from volume-led growth to value- and innovation-led expansion is currently the defining trend of the Indian pharmaceutical business
Lupin has unveiled an ambitious tactical plan aimed at accelerating its growth through a strong product pipeline, widened market reach, and improved financial health. The company's latest update emphasizes a tightly managed approach
Torrent Pharmaceuticals got the green light from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) to produce and sell Prucalopride Oral Solution (0.2 mg/mL).
.jpg)
, CDSCO.jpg)